Search Results

Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381) MOA: Tucatinib is an oral tyrosine kinase inhibitor selective for HER2 Doxil is an anthracycline topoisomerase II inhibitor Key Eligibility Criteria: Women, men with HER2+ metastatic breast cancer (IHC3+ or…

Understanding Mammogram Recalls Tech capturing image during a routine mammogram It is not unusual to get recalled after an initial screening mammogram. Additional imaging is often requested so that a clearer view of a particular area of breast tissue can be captured. Fewer than one in 10 women who return for additional testing are found…

A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) MOA: Capivasertib is an oral pan-AKT inhibitor Key Eligibility Criteria: Men and women with adv/metastatic HR+/HER2- breast cancer Pre-/perimenopausal…

A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy  (eVOLVE-HNSCC) MOA: Checkpoint inhibitor Volrustomig (MEDI5752): Monovalent, bispecific, anti-PD-1 / anti-CTLA-4 humanized IgG1 mAb Key Eligibility Criteria: Locally advanced squamous…

Marissa Davidson, DNP, earned her associate degree in nursing at Morrisville State University, where she was awarded the Distinguished Nurse Award for academic excellence. She then went on to earn a bachelor’s degree in nursing at Chamberlain University. In May 2024, she graduated from the University of Maryland School of Nursing with a Doctor of…